News

2025 Podcasts: Year in Review

Celebrate the achievements, guests and breakthroughs for the TOGA Podcast ‘Conversations in Lung Cancer Research’.

As the year draws to a close, the Podcast team is taking a moment to celebrate the incredible chairs, guests, groundbreaking discussions, and you, our dedicated listeners, that made this our most successful year yet.

In 2025, we re-branded the podcast series to ‘Conversations in Lung Cancer Research’, produced an interview format hosted by A/Prof Mel Moore to highlight the incredible members of TOGA, released 14 new episodes (+40% YoY), and increased our downloads by 110% YoY

To close out the year, we want to shout out the guests and episodes from Conversations in Lung Cancer Research that represented the very best in thoracic oncology research, clinical practice, and TOGA spirit.

Top Podcast Contributor: A/Prof Mal Itchins

We want to recognise an individual whose ongoing support, insights, and energy have consistently enriched our podcast and the broader TOGA community.

A/Prof Mal Itchins is a generous member of TOGA. With six appearances on the podcast, including two episodes this year (and another recording on the way), Mal is a true podcast veteran. 

Not only does she contribute invaluable clinical expertise to the industry through her talks at education events, she also embodies dedication through her fundraising efforts. Thank you for your continued support, enthusiasm, and insight!

Listen to A/Prof Mal Itchins in The Role of Liquid Biopsy in Modern Oncology:

Listen to Exploring EGFR Exon 20 Insertion Mutations:

Episode that Broke TOGA Records: Vaccines in Thoracic Oncology

With well over 1,000 listens, this episode featuring special guest Prof Georgina Long, alongside Prof Tom John and Prof Ken O’Byrne, became our most popular of the year and highest listens ever. 

The discussion was timely and cutting-edge, delving into the technological advances spurred by COVID-19 vaccine development. The panel explored promising results from recent melanoma and lung cancer vaccine trials, and the enormous potential for personalised neoantigen mRNA vaccines to change the treatment landscape. If you missed this one, it’s a must-listen!

Listen to Vaccines in Thoracic Oncology: The Next Frontier in Immunotherapy

Best Inspirational Quote: A/Prof Bryan Chan

Every year, a guest delivers a quote that truly resonates, offering advice that extends far beyond the clinical world. This year, the winner is Bryan for a powerful message about professional growth and managing self-doubt:

“In terms of getting yourself out there, look it is scary at the beginning and even now everyone has imposter syndrome… but you do have to say yes to things. So when invited, rather than think of reasons why you might not be the best person to take the challenge, say, ‘okay, how can I best do this?’ And if you fail, well you fail. Just try again harder next time. But, I do think, especially in the beginning, it is about accepting challenges and rising to them.”

As this year’s ASM Convenor, this quote from Bryan is a fantastic reminder that courage, a willingness to fail, and the simple act of saying “yes” are the keys to professional advancement in a challenging field.

Listen to Bryan’s episode: 

Episode with the Best Deep Dive: Optimising Lung Cancer Treatment in Older Adults

The Best Deep Dive recognises the episode that tackles a topic with exceptional clarity, detail, and compassion.

Hosted by Dr Michael Krasovitsky, this episode of Conversations in Lung Cancer Research expertly focused on the nuances of lung cancer treatment in older adults. The comprehensive discussions with experts A/Prof Christopher Steer, Prof Shalini Vinod, and Ms Nicole Webb explored:

  • Critical distinction and application of geriatric oncology

  • The importance of conducting geriatric assessments

  • Unique challenges and necessity of tailored, supportive care

  • The pervasive impact of ageism in cancer treatment decision-making

This conversation provided practical tools for assessing frailty and underscored the critical need for an open, compassionate, and holistic approach to cancer care in this population. It was an essential and educational listen.

Listen to Challenging Ageism: Optimising Lung Cancer Treatment in Older Adults

Thanks to You

Thank you to all of our award winners, every single guest who shared their time, and especially to our listeners for tuning in, sharing, and engaging with the Conversations in Lung Cancer Research Podcast

We took a risk with a rebrand of the podcast this year and we couldn’t have done it without your support to make this season of episodes the most successful yet! We look forward to bringing you more stories from TOGA members and current edge research in the new year!

Share this

Facebook
Twitter
LinkedIn
Learn what a KRAS G12C mutation means, how targeted therapies work, and how Australian clinical trials are testing new lung cancer treatments.
The PHARAOH-A trial will evaluate savolitinib plus osimertinib in MET-positive amplified or overexpressed EGFR-mutated lung cancer after progression on prior TKI and chemotherapy.
New evidence is changing the way surgeons approach early-stage lung cancer, with lung-sparing surgery becoming an option for carefully selected patients.
Everything you need to know about the Australia-wide trial using liquid biopsy to guide treatment after targeted therapy progression in advanced lung cancer
The DEFIANT trial will evaluate datopotamab deruxtecan (Dato-DXd) in EGFR exon 20 insertion NSCLC after targeted therapy and chemotherapy.
Discover the major advances from TOGA ASM 2026, including lung cancer screening, precision medicine, immunotherapy, survivorship and multidisciplinary care shaping the future of thoracic oncology.
Professor Robert Stirling OAM devoted his career to improving the lives of people with lung cancer through clinical excellence, research, education and compassionate leadership.
Their work is often invisible, but its impact isn't. Specialist Lung Cancer Nurses are quietly becoming the backbone of modern lung cancer care.
Teletrials, also known as digi trials, are when a clinician at a primary site uses telehealth (videoconference or telephone calls) to enrol, consent, treat and/or
A simple guide to what happens after a lung CT scan in the Australian National Lung Cancer Screening Program
Updates from our Inspirational Research Grant 2025 recipients on pioneering lung microbiome research and its impact on immunotherapy efficacy.
Clinicians, nurses, consumers and health service leaders came together at TOGA’s Lung Cancer Optimal Care Pathway workshop to examine why Australia continues to struggle to
Understanding the language helps patients, families and clinicians stay informed, confident and part of the conversation.
TOGA is pleased to announce the latest appoints for our Scientific Committee.
Discover how a vibrant Lunar New Year Banquet, organised by Dr. Angeline Low and Ms. Maria Chan, raised over $50,000 for vital lung cancer research.
The MRFF is holding $1B+ in unspent funds. Learn why TOGA is calling for the release of this research funding to accelerate lung cancer breakthroughs
Discover TOGA’s FY25 highlights, including the new Strategic Plan, clinical trial milestones and record membership growth across Australia and New Zealand.
The Preventative and Quality Care Working Group represents TOGA’s commitment to improving the outcomes of thoracic cancers.
TOGA’s Working Groups are evolving to better reflect where thoracic cancer research is heading: From prevention and early detection through to advanced disease and living
Learn how to turn your endorsed research concept into a clinical trial; from sponsor selection to budgeting, data, safety and protocol design.
Learn how to design an investigator-initiated clinical trial, from refining your research idea to securing TOGA endorsement and funding.
Learn why EGFR-positive lung cancer disproportionately affects Asian populations and non-smokers. Discover modern targeted therapies and symptoms to watch for.
Discover how 2025 transformed lung cancer care in Australia. Explore the impact of national screening, modern diagnostics, and new PBS treatment approvals.
If you are interested in joining TOGA on a Committee, please submit your nominations by 30 January 2026
The final Scientific Meeting of 2025 was held in November. Five concepts were presented, spanning both Recurrent and Metastatic NSCLC populations and four Mesothelioma concepts.
Bispecific antibodies target two pathways at once, reshaping lung cancer treatment through dual checkpoint blockade and targeted precision.
Research advances only improve outcomes when they are accessible to patients. TOGA drives change in lung cancer care by advocating through stakeholder submissions, including PBS.......
We are excited about awarding new grants but first, we check in on progress made by our 2024 recipients....
Learn how TOGA’s ASPiRATION study led to Medicare-funded genomic testing for lung cancer and national best practice guidelines in Australia.
Optimise cancer care for older Adults with practical tips and tools to implement person-centred geriatric oncology.
DYNAMALK is a significant clinical trial investigating the potential of comprehensive genomic profiling to revolutionise the treatment of ALK+ Non-Small Cell Lung Cancer (NSCLC)
Liquid biopsy is revolutionising lung cancer care by using a blood test to examine the tumour without the need for a lung biopsy.
OCEANiC will determine if patients with resected stage II to IIIA EGFR mutant NSCLC require intensification of osimertinib monotherapy with chemotherapy.
Latest results from the SHERLOCK clinical trial show promising first-line outcomes for patients with KRAS G12C-mutated lung cancer, combining sotorasib with chemotherapy and bevacizumab.
A re-cap of the Scientific Committee meeting in August 2025 and the year to date.
Celebrating TOGA's leadership transition: We honour the service of our past Board members and welcome the new Chair and Directors who will chart TOGA’s future.